Selective NNMT Inhibitor & NAD+ Preserver
5-Amino-1MQ is a small, membrane-permeable molecule that acts as a highly selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). By inhibiting NNMT, 5-Amino-1MQ prevents the depletion of NAD+ and over-methylation in adipose tissue, leading to a significant increase in cellular energy expenditure and the reduction of white adipose tissue volume. It is a premier research compound for studying cellular metabolism, obesity, and age-related metabolic decline.
Initial NNMT inhibition and stabilization of intracellular NAD+ levels. Subjects exhibit mild thermogenic effects without changes in appetite.
| Compound | Primary Mechanism | Key Benefit | Admin. |
|---|---|---|---|
| 5-Amino-1MQ | NNMT Inhibitor | Targeted white adipose reduction | Oral/SubQ |
| MOTS-c | Mitochondrial Peptide | Systemic metabolic homeostasis | SubQ |
| Tirzepatide | GLP-1/GIP Agonist | Appetite suppression & glycemic control | SubQ |
| Tesamorelin | GHRH Analogue | Visceral fat reduction | SubQ |
5-Amino-1MQ targets the root cause of age-related metabolic slowdown by blocking the enzyme responsible for draining cellular energy reserves.
Selectively blocks Nicotinamide N-methyltransferase in white adipose tissue, an enzyme that is often overexpressed in obese models.
Prevents the methylation of nicotinamide, allowing it to be recycled back into NAD+ via the salvage pathway, effectively "plugging the leak" in cellular energy.
Increased NAD+ levels activate sirtuins (SIRT1), enhancing mitochondrial biogenesis and resting energy expenditure.
Relatively short half-life requiring consistent dosing in research models.
Membrane-permeable, allowing for high intracellular concentration and target engagement.
Cleared via renal pathways following cellular metabolism.
Specifically targets and binds to the active site of the NNMT enzyme.
5-Amino-1MQ has demonstrated profound efficacy in reversing diet-induced obesity in animal models without altering food intake.
Explores how preserving NAD+ levels impacts overall cellular metabolism.
OBESITY RESEARCHA deep dive into 5-Amino-1MQ's unique mechanism for fat reduction.
AGINGReviews the compounded metabolic effects of inhibiting NNMT in aging models.
Explore research-use products associated with this compound profile, including available formats, related blends, and supporting lab documentation where available.
Deeper research-focused questions about 5-Amino-1MQ, NNMT inhibition, nicotinamide metabolism, NAD+ salvage pathway research, methylation biology, adipocyte models, storage, and batch documentation.
5-Amino-1MQ, also written as 5-amino-1-methylquinolinium, is a small-molecule research compound commonly discussed as an inhibitor of nicotinamide N-methyltransferase, also called NNMT. In research contexts, 5-Amino-1MQ is studied around NAD+ salvage pathway biology, nicotinamide metabolism, methylation pathway regulation, adipocyte models, energy homeostasis, and metabolic tissue signaling. On this site, 5-Amino-1MQ is positioned strictly as a laboratory research reference compound.
5-Amino-1MQ is shorthand for 5-amino-1-methylquinolinium. The name describes a methylquinolinium-based chemical structure with an amino group at the 5-position. Because the full chemical name is longer, many research suppliers and educational pages abbreviate it as 5-Amino-1MQ or 5A1MQ. For SEO clarity, it is useful to include both the abbreviation and the full chemical name on the page.
No. 5-Amino-1MQ is not a peptide. Peptides are made from amino acid chains, while 5-Amino-1MQ is a small-molecule methylquinolinium research compound. For site structure and SEO, it should be described as a research compound, small-molecule inhibitor, methylquinolinium compound, or NNMT inhibitor rather than being grouped chemically with peptide pages such as BPC-157, TB-500, GHK-Cu, or CJC-1295.
NNMT stands for nicotinamide N-methyltransferase. It is an enzyme involved in the methylation of nicotinamide and is commonly discussed in research involving NAD+ metabolism, methyl donor balance, one-carbon metabolism, adipose tissue biology, and cellular energy regulation. Because NNMT connects nicotinamide handling with methylation biology, it has become an important target in metabolic and epigenetic research models.
5-Amino-1MQ is commonly discussed as a selective small-molecule inhibitor of NNMT. In research models, NNMT inhibition is studied because it may change how cells handle nicotinamide, NAD+ precursor availability, methyl donor usage, and downstream metabolic signaling. This makes 5-Amino-1MQ different from receptor agonist compounds because its research focus is centered on enzyme inhibition and metabolic pathway regulation rather than receptor activation.
NNMT is important because it sits at the intersection of nicotinamide metabolism and methylation biology. The enzyme methylates nicotinamide, which connects it to NAD+ salvage pathway research, while also using methyl donor resources that are relevant to one-carbon metabolism and epigenetic regulation. This is why 5-Amino-1MQ pages should mention both NAD+ pathway research and methylation pathway research instead of describing the compound only as a metabolic or weight-related molecule.
5-Amino-1MQ is studied in adipocyte and metabolic research because NNMT has been investigated in relation to adipose tissue function, cellular energy homeostasis, nicotinamide metabolism, methyl donor balance, and diet-induced metabolic models. Educational content should frame this as preclinical metabolic pathway research, not as a human weight-loss claim, wellness claim, or treatment claim. This keeps the page scientifically cleaner and better aligned with a research-use-only catalog.
5-Amino-1MQ is different from NAD+, NMN, and NR because it is usually discussed as an NNMT inhibitor rather than as a coenzyme or NAD+ precursor. NAD+ is a dinucleotide coenzyme involved in redox metabolism, while NMN and NR are commonly discussed as NAD+ precursor molecules. 5-Amino-1MQ is positioned around enzyme inhibition and pathway regulation that may influence nicotinamide handling and NAD+ salvage pathway research indirectly.
5-Amino-1MQ is mechanistically different from Retatrutide, Semaglutide, Tirzepatide, and other incretin-pathway compounds. Retatrutide is commonly discussed around GIP, GLP-1, and glucagon receptor pathway research, while GLP-1 compounds focus on receptor agonist biology. 5-Amino-1MQ is instead centered on NNMT enzyme inhibition, nicotinamide metabolism, NAD+ pathway research, and methylation-related metabolic models. These compounds belong on separate resource pages because the mechanisms and SEO search intent are very different.
No. 5-Amino-1MQ is not the same type of compound as MOTS-c or AOD-9604. MOTS-c is usually discussed as a mitochondrial-derived peptide, while AOD-9604 is commonly discussed as a peptide fragment associated with growth hormone fragment research. 5-Amino-1MQ is better categorized as a small-molecule NNMT inhibitor used in metabolic pathway and enzyme-inhibition research. It may appear near metabolic compounds in a catalog, but it should not be chemically described as a peptide.
5-Amino-1MQ is commonly associated with research areas involving NNMT inhibition, nicotinamide metabolism, NAD+ salvage pathway biology, methylation pathway regulation, adipocyte models, metabolic tissue signaling, cellular energy homeostasis, insulin sensitivity models, one-carbon metabolism, and epigenetic regulation. It is best positioned as a small-molecule metabolic enzyme inhibitor rather than a peptide, hormone-axis compound, melanocortin compound, or direct receptor agonist.
5-Amino-1MQ research discussions may involve endpoints related to NNMT enzyme activity, nicotinamide methylation, NAD+ salvage pathway markers, methyl donor balance, SAM-related methylation pathways, adipocyte size models, adipose tissue gene expression, metabolic enzyme activity, insulin sensitivity models, and mitochondrial or cellular energy markers. The exact endpoints depend on the study model, analytical methods, tissue system, and whether the research focuses on adipose biology, enzyme inhibition, or metabolic pathway regulation.
5-Amino-1MQ should not be presented as an approved medication, dietary supplement, weight-management product, wellness product, anti-aging product, or self-administered therapy. Research-use material sold by Symbiotic Pharmaceuticals should not be confused with any regulated pharmaceutical product, clinical protocol, or consumer health product. This page is written only for educational reference and laboratory research positioning.
Storage requirements can vary by product format, salt form, batch, and label instructions. For research handling, follow the product label and applicable laboratory storage standards. In general, research compounds should be protected from unnecessary heat, light, moisture, contamination, and repeated temperature changes because these conditions may affect long-term stability and handling quality.
Available certificates of analysis and batch documentation can be reviewed through the Lab Results / COA page. Documentation availability may vary by product and inventory lot. Where available, batch documentation may include product identification, purity-focused testing references, and supporting analytical documentation.
Yes. 5-Amino-1MQ products listed on Symbiotic Pharmaceuticals are intended for laboratory research and analytical reference use only. They are not intended for human consumption, animal consumption, diagnostic use, therapeutic use, weight-management use, anti-aging use, metabolic treatment, supplement use, injection use, or self-administration. Any discussion on this page is provided for educational and research-reference purposes only.
The information provided in this resource hub is for educational and informational purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease.
